新功能、新界面、新体验,扫描即可下载生物谷APP!
首页 » 投资 » 谷歌风投:2015年将继续保持在生物医药产业投资力度

谷歌风投:2015年将继续保持在生物医药产业投资力度

来源:生物谷 2014-12-17 13:35

2014年12月17日讯 /生物谷BIOON/ --近年来,生物医药产业的发展也促进了生物医药与其他多个领域的交融。例如,目前大规模临床研究的兴起对患者数据处理提出了很高的要求,这也使得IT产业大数据概念被生物医药研发人员广泛接受,著名的互联网公司谷歌也得以进入广大生物医药分析人士的视线中。

在今年下半年,谷歌公司宣布加入到美国政府提出的BRAIN计划中,也引起了业界的高度关注。(相关阅读:谷歌加入脑计划(BRAIN)提供数据处理服务)此前,谷歌公司旗下的Calico与UT Southwestern达成协议合作开发治疗神经退行性疾病药物,更是被认为是谷歌进入生物医药领域的一个重要标志。(相关阅读:谷歌旗下Calico与UT Southwestern达成协议合作开发治疗神经退行性疾病药物

不过,谷歌与生物医药产业的缘分,显然不止于此。

谷歌旗下的谷歌风投在过去几年中不断保持着在生物医药产业的投资力度。2013年,谷歌风投总计4亿2千5百万美元的风投资金中仅有9%进入了生物医药产业中。而到了今年,这一数字激增至三分之一之多。

最近谷歌投资的投资人Bill Maris在接受采访中表示,2015年公司在生物医药产业的投资力度将不低于2014年的水平。同时,相较于以往,最近两年谷歌风投在生物医药产业的投资对象呈现出两极分化的趋势。公司的一部分投资倾斜于专注于生物基因组数据分析公司,如23andMe, Foundation Medicine ($FMI), DNAnexus 和Flatiron Health等。这些公司主要是为各个生物医药项目提供数据分析支持。另一方面,公司将相当大的一部分资金投入到传统医药研发的项目中,这其中包括了抗体药物开发公司 Adimab和大分子药物开发公司Rani Therapeutics等。

同时,谷歌在其专门从事创新研发部门Google X中专门设立了生物医药团队,也足以说明谷歌公司对生物医药领域的重视。除此之外,谷歌公司旗下的一些公司还纷纷与施贵宝公司等生物医药巨头签订了合作协议,帮助谷歌公司进一步进入这一新兴产业。(生物谷Bioon.com)

详细英文报道:

Google Ventures is betting more and more on life sciences startups each year, and the well-funded financier tells The Wall Street Journal that's not going to change in the new year.

In 2014, Google ($GOOG) poured more than one-third of its $425 million venture fund into healthcare and life sciences companies, lead investor Bill Maris told WSJ, up from just 9% in 2013. And, rolling into next year, Maris expects Google Ventures to maintain roughly the same dollar value and strategic focus.

The shift is two-pronged, Maris said. For one, Google sees an explosion of potential in the space thanks to the rise of genomics and availability of patient data. Separately, the traditional consumer tech world, where Google Ventures has long been a player, is getting bubbly, with valuations creeping out of control.

"Barring some huge calamity, we'll see more interesting things in life sciences in 2015," Maris told WSJ.

Google Ventures isn't getting into specifics on its life sciences strategy, but if the group's existing portfolio is any indication, it'll have a genomic bent. Among Google's beneficiaries are 23andMe, Foundation Medicine ($FMI), DNAnexus andFlatiron Health, companies that sequence, analyze and index genomic data. But the company has placed plenty of bets on more traditional biotech outfits, as well, including antibody specialist Adimab, large-molecule developer Rani Therapeutics and iPierian, since acquired by Bristol-Myers Squibb ($BMY) for up to $725 million.

Google's deeper dive into life sciences goes beyond its venture arm. Last year, the company expanded its secretive, R&D-focused Google X unit to include a dedicated life sciences team, spurring rumors that the tech giant is planning to make major waves in the field of wearable health devices.

And then there's Calico, a Google-funded biotech with the vague mission of battling aging and a star-studded staff to lead the effort. Short for California Life Company, the startup got off the ground last year with Genentech veterans Art Levinson and Hal Barron leading a team of well-regarded researchers, and Calico has since inked a research deal with AbbVie ($ABBV) to get rolling on an R&D operation that could cost up to $1.5 billion.

 

温馨提示:87%用户都在生物谷APP上阅读,扫描立刻下载! 天天精彩!


相关标签

最新会议 培训班 期刊库